

STIC-ILL

460,347

RS1.E9

NOS 8/19

From:  
Sent:  
To:  
Subject:

Wilson, Michael  
Monday, August 18, 2003 4:03 PM  
STIC-ILL  
art req. 09/993159

TI Histamine receptors

AU Watanabe, Takehiko; Yanai, Kazuhiko; Fukui, Hiroyuki

SO Tanpakushitsu Kakusan Koso (1997), 42(3), 327-334

CODEN: TAKKAJ; ISSN: 0039-9450

PB Kyoritsu

LA Japanese

TI Histamine H1 receptor-mediated inhibition of potassium-evoked release of 5-hydroxytryptamine from mouse forebrains.

AU Son L Z; Yanai K; Mobarakeh J I; Kuramasu A; Li Z Y; Sakurai E; Hashimoto

SO BEHAVIOURAL BRAIN RESEARCH, (2001 Oct 15) 124 (2) 113-20.

TI IMPROGAN, A HISTAMINE DERIVATIVE, INDUCES ANTINOCICEPTION IN HISTAMINE

RECEPTOR - DEFICIENT MUTANT MICE.

COMPLETED

AU Hough, L. B. (1); Nalwalk, J. W. (1); Mobarakeh, J. I.; Yanai, K.; Stadel, J.

SO Society for Neuroscience Abstract Viewer and Itinerary Planner, (2002)

Vol. 2002, pp. Abstract No. 156.15. <http://sfn.scholarone.com>. cd-rom.

Meeting Info.: 32nd Annual Meeting of the Society for Neuroscience

Orlando, Florida, USA November 02-07, 2002 Society for Neuroscience.

DT Conference

12798951

TI Activation of spinal histamine H3 receptors inhibits mechanical nociception

AU Cannon, Keri E.; Nalwalk, Julia W.; Stadel, Rebecca; Ge, P.; Lawson, D.;

SO European Journal of Pharmacology (2003), 470(3), 139-147

## Activation of spinal histamine H<sub>3</sub> receptors inhibits mechanical nociception

Keri E. Cannon<sup>a</sup>, Julia W. Nalwalk<sup>a</sup>, Rebecca Stadel<sup>a</sup>, P. Ge<sup>b</sup>, D. Lawson<sup>b</sup>,  
I. Silos-Santiago<sup>b</sup>, Lindsay B. Hough<sup>a,\*</sup>

<sup>a</sup>Center for Neuropharmacology and Neuroscience, Albany Medical College MC-136, 47 New Scotland Ave., Albany, NY 12206, USA

<sup>b</sup>Millennium Pharmaceuticals Inc., Cambridge, MA, USA

Received 12 December 2002; received in revised form 9 April 2003; accepted 15 April 2003

### Abstract

Previous studies have suggested a possible pain-modulatory role for histamine H<sub>3</sub> receptors, but the localization of these receptors and nature of this modulation is not clear. In order to explore the role of spinal histamine H<sub>3</sub> receptors in the inhibition of nociception, the effects of systemically (subcutaneous, s.c.) and intrathecally (i.t.) administered histamine H<sub>3</sub> receptor agonists were studied in rats and mice. Immeipip (5 mg/kg, s.c.) produced robust antinociception in rats on a mechanical (tail pinch) test but did not alter nociceptive responses on a thermal (tail flick) test. In contrast, this treatment in mice (immeipip, 5 and 30 mg/kg, s.c.) did not change either mechanically or thermally evoked nociceptive responses. When administered directly into the spinal subarachnoid space, immeipip (15–50 µg, i.t.) and R-α-methylhistamine (50 µg, i.t.) had no effect in rats on the tail flick and hot plate tests, but produced a dose- and time-dependent inhibition (90–100%) of nociceptive responses on the tail pinch test. This attenuation was blocked by administration of thioperamide (10 mg/kg, s.c.), a histamine H<sub>3</sub> receptor antagonist. Intrathecally administered thioperamide also reversed antinociceptive responses induced by systemically administered immeipip, which demonstrates a spinal site of action for the histamine H<sub>3</sub> receptor agonist. In addition, intrathecally administered immeipip (25 µg) produced maximal antinociception on the tail pinch test in wild type, but not in histamine H<sub>3</sub> receptor knockout (H<sub>3</sub>KO) mice. These findings demonstrate an antinociceptive role for spinal histamine H<sub>3</sub> receptors. Further studies are needed to confirm the existence of modality-specific (i.e. mechanical vs. thermal) inhibition of nociception by these receptors, and to assess the efficacy of spinally delivered histamine H<sub>3</sub> receptor agonists for the treatment for pain.

© 2003 Elsevier Science B.V. All rights reserved.

**Keywords:** H<sub>3</sub> receptor; Immeipip; Antinociception

### 1. Introduction

Histamine is released from neuronal and non-neuronal (i.e. mast cell) sources and exerts its actions through several receptors, including the histamine H<sub>3</sub> receptor (Hough, 2001). Although histamine H<sub>3</sub> receptors were initially discovered to be presynaptic inhibitory autoreceptors in the brain (Arrang et al., 1983), lesion studies revealed the majority of histamine H<sub>3</sub> receptors are inhibitory heteroreceptors located on postsynaptic neurons (Pollard et al., 1993). Biochemical studies confirmed that the histamine H<sub>3</sub> receptor is a pertussis toxin-sensitive, G<sub>i</sub>/G<sub>o</sub>-coupled, trans-

membrane receptor linked to the inhibition of adenylate cyclase and to other pathways (Clark and Hill, 1996; Morisset et al., 2000; Lovenberg et al., 1999; Drutel et al., 2001). Histamine H<sub>3</sub> receptor binding sites are found in high densities in the cerebral cortex, hippocampus, olfactory nucleus, and striatum, while lower binding densities are found in the noradrenergic and serotonergic neurons of the brainstem and superficial dorsal horn of the spinal cord (Pollard et al., 1993). The cloning of human (Lovenberg et al., 1999), rat (Lovenberg et al., 2000), and guinea pig (Tardivel-Lacombe et al., 2000) histamine H<sub>3</sub> receptor genes has led to the discovery of multiple isoforms in each species (Drutel et al., 2001; Tardivel-Lacombe et al., 2000; Cogé et al., 2001; Wellendorph et al., 2002).

Several pharmacological agents have allowed the role of histamine H<sub>3</sub> receptors in physiological processes to be elucidated. One such tool is thioperamide, the first selective

\* Corresponding author. Tel.: +1-518-262-5785; fax: +1-518-262-5799.

E-mail address: [houghl@mail.amc.edu](mailto:houghl@mail.amc.edu) (L.B. Hough).

antagonist developed for the histamine  $H_3$  receptor (Arrang et al., 1987). Thioperamide inhibits radiolabeled histamine  $H_3$  receptor binding in rat cerebral cortex membranes with a  $K_i$  of 2.1 nM (Arrang et al., 1987) and remains the prototypical histamine  $H_3$  receptor antagonist used for in vivo and in vitro research (Hill et al., 1997). The first selective histamine  $H_3$  receptor agonist R- $\alpha$ -methylhistamine has been widely used as a potent in vivo tool, as well as a useful radioligand for characterizing the role of histamine  $H_3$  receptors in physiological processes (Hill et al., 1997). R- $\alpha$ -methylhistamine has high affinity for the histamine  $H_3$  receptor, giving a  $pD_2$  of 7.8 on electrically evoked twitches of the guinea pig jejunum (Vollinga et al., 1994). However, several limitations of R- $\alpha$ -methylhistamine exist, including poor blood–brain barrier penetration due to its highly polar structure (Taylor et al., 1992; Rouleau et al., 1997, 2000). In addition, at higher concentrations R- $\alpha$ -methylhistamine can act at histamine  $H_1$  receptors (Hey et al., 1992). Finally, R- $\alpha$ -methylhistamine is also a substrate for histamine  $N$ -methyltransferase, the histamine-metabolizing enzyme, causing rapid inactivation of the drug in humans (Rouleau et al., 1997, 2000). Therefore, the pro-drug (*R*)-(–)-2-[[*N*-[1-(1 *H*-imidazol-4-yl)-2-propyl]imino]phenylmethyl]phenol (referred to as BP 2-94) was developed to slowly metabolize into the desired active metabolite, R- $\alpha$ -methylhistamine (Krause et al., 1995). BP 2-94 succeeded in achieving sustained plasma levels of R- $\alpha$ -methylhistamine in humans, but this drug failed to penetrate the brain in rodents (Rouleau et al., 1997).

Other highly selective histamine  $H_3$  receptor agonists have been developed, including immepip (Vollinga et al., 1994). Immepip is a potent histamine  $H_3$  receptor agonist ( $pD_2$  of 8.0 on electrically evoked twitches of the guinea pig jejunum). Unlike R- $\alpha$ -methylhistamine, immepip is not a substrate for histamine  $N$ -methyltransferase, and it lacks activity at the histamine  $H_1$  receptor (Hough and Leurs, 2002). Furthermore, immepip may penetrate the brain (Jansen et al., 1998) and spinal cord after systemic administration, thus providing a better tool for studying the role of histamine  $H_3$  receptors in vivo.

Localization of histamine  $H_3$  receptors on sensory fibers has been suggested by several laboratories (Imamura et al., 1996; Ohkubo et al., 1995; Delaunois et al., 1995; Nemmar et al., 1999). Imamura et al. (1996) demonstrated a histamine  $H_3$  receptor-induced inhibition of bradykinin-induced or capsaicin-induced release of calcitonin gene-related peptide from cardiac tissues. Delaunois et al. (1995) showed that histamine  $H_3$  receptor agonists inhibited acetylcholine- and capsaicin-induced edema in isolated rabbit lungs, thus suggesting the presence of prejunctional histamine  $H_3$  receptors on C fibers. In addition, the histamine  $H_3$  receptor agonist R- $\alpha$ -methylhistamine was shown to inhibit the release of substance P from peripheral sciatic nerve endings of rats (Ohkubo et al., 1995).

Since nociceptive (i.e. pain) transmission is conveyed by A $\delta$  and C sensory fibers, and histamine  $H_3$  receptors have

been suggested to inhibit the activity of sensory fibers, then histamine  $H_3$  receptor agonists could inhibit nociceptive transmission and show promise as analgesics. However, relatively few studies (Rouleau et al., 1997, 2000) have focused on antinociceptive effects of histamine  $H_3$  receptor agonists. Oral administration of the prodrug BP 2-94 in mice reduced capsaicin-induced licking in mice (Rouleau et al., 2000) and inhibited nociceptive responses on the phenylbenzoquinone writhing test and on both phases of the formalin test (Rouleau et al., 1997). However, BP 2-94 failed to produce antinociceptive effects on the hot plate test (Rouleau et al., 1997). Because neither BP 2-94 nor its active metabolite R- $\alpha$ -methylhistamine were detectable in the brain (Rouleau et al., 1997), the mixed antinociceptive actions of BP 2-94 could be due to poor central nervous system penetration or to a limited role for the histamine  $H_3$  receptor in pain modulation. The present work addresses the blood–brain barrier problem by assessing the antinociceptive activity of intrathecally (i.t.) and systemically (subcutaneously, s.c.) administered histamine  $H_3$  receptor agonists.

## 2. Methods and materials

### 2.1. Animals

All experiments were approved by the Institutional Animal Care and Use Committee of Albany Medical College. Male Sprague–Dawley rats (300–350 g, Taconic Farms, Germantown, NY), housed in groups of two or three per cage, and female wild type or histamine  $H_3$  receptor knockout mice ( $H_3$ KO, 10–14 weeks old, 20–30 g), housed up to seven per cage, were maintained on a 12 h light/dark cycle (lights on from 7:00 to 19:00 h). Food and water were provided ad libitum.

Histamine  $H_3$  receptor knockout ( $H_3$ KO) mice were generated by targeted deletion of exon 3 of the mouse histamine  $H_3$  receptor gene. The  $H_3$ KO targeting vector, constructed by homologous recombination in yeast (Storck et al., 1996), consisted of a lacZ-neo-URA3 cassette that replaced all but the first 45 base pairs of exon 3 and 300 base pairs of the intronic sequence downstream of exon 3. The targeted embryonic stem cell clones (129/SvEv cells) were produced by electroporation, confirmed by Southern blots, and injected into C57BL/6J blastocysts to generate chimeras. Male chimeras were mated with C57BL/6J females, and their heterozygous offspring were interbred to generate F2 progeny. Polymerase chain reaction (PCR) was performed to genotype the resulting progeny. Mendelian inheritance patterns were seen in offspring from heterozygous matings.  $H_3$ KO mice showed no detectable histamine  $H_3$  receptor mRNA in the brain or the spinal cord by in situ hybridization. Brains from these subjects also had no detectable histamine  $H_3$  receptor binding as assessed with [ $^3$ H]R- $\alpha$ -methylhistamine (Harper et al.,

1999). Further characterization of these  $H_3KO$  mice is being reported elsewhere (manuscript in preparation). In addition, two other laboratories have recently generated and characterized  $H_3KO$  mice (Toyota et al., 2002; Takahashi et al., 2002).

## 2.2. Drugs

Immepip 2 HBr (kindly provided by Professor R. Leurs, Vrije University, Amsterdam, Netherlands), R- $\alpha$ -methyl-histamine 2 HCl (kindly provided by Dr. C. Tedford, Gliatech, Cleveland, OH), and thioperamide maleate (Tocris, Ellisville, MO) were dissolved in saline and neutralized with 1 N NaOH to pH 6.5. All doses are expressed as bases.

## 2.3. Surgery

For rat intrathecal injections, the spinal subarachnoid space was chronically cannulated under general anesthesia as described previously by Yaksh and Rudy (1976) with modifications (Hammond, 1988). The animals were then placed in separate cages and allowed to recover for a minimum of 10 days.

## 2.4. Nociceptive tests

Three nociceptive tests were performed in rats. For the hot plate test (Eddy and Leimbach, 1953), the rats were placed on a 52 °C metal surface and the latency for a hind paw lift or lick was recorded. Baseline latencies were between 8 and 14 s. Animals not responding within 60 s (cutoff) were removed from the heat source. For the tail flick test (D'Amour and Smith, 1941), the ventral surface of the rat's tail (approximately 2–5 cm from the tip) was exposed to radiant heat and the latency of tail removal from the heat was recorded. Baseline latencies were between 3 to 4 s with a 15-s cutoff. For the tail pinch test (Bianchi and Franceschini, 1954), rats were placed in a clean cage and an alligator clip exerting force equal to 625 g of weight was placed on the tail towards the tip (approximately 5–10 cm from the tip). The latency for vocalization, biting, or flicking the clip was recorded. Baseline latencies fell between 15 and 25 s with a 90-s cutoff.

Two nociceptive tests were performed in mice. In the tail immersion test (Sewell and Spencer, 1976), mice were loosely restrained in a conical polypropylene tube. The tip (2–3 cm) of the tail was immersed into a 55 °C water bath and the latency to the flick or removal of the tail from the water was recorded. Baseline latencies fell between 1 and 3 s with an 8-s cutoff. For the tail pinch test (Bianchi and Franceschini, 1954), a microserrafine arterial clip (Fine Science Tools, Foster City, CA) was placed at the base of the tail. The latency for vocalization, biting, or flicking the clip was recorded. Baseline latencies fell between 0.5 and 2 s with a 30-s cutoff.

## 2.5. Rat test procedure

Rats were tested at 60 s intervals with a single hot plate test, three tail flick tests, and a single tail pinch test. The sequence of nociceptive tests was performed with 60 s intervals separating the tests. Subjects were then secured in a laboratory pad for intrathecal injection. The seal at the free ending of the chronic catheter was removed and a 10  $\mu$ l manual injection was made over 1 min followed by a 10  $\mu$ l flush of saline over 1 min. Movement of an air bubble between the tubing and the syringe, as well as absence of leakage, ensured successful intrathecal injections. Following intrathecal injection, the catheter was heat-sealed, and rats were tested at 60 s intervals with single hot plate, tail flick, and tail pinch tests. Following the experiments, successful cannulations were verified by observing cut-off responses on the tail flick test after a 10  $\mu$ g morphine sulfate intrathecal injection. Some rats were baseline tested and received systemically administered drug prior to intrathecal injection. For systemic injections in rats, subjects received a single baseline tail flick and tail pinch tests.

## 2.6. Mouse test procedure

Intrathecal injections were made exactly as described by Hylden and Wilcox (1980). Mice were first baseline tested on the tail immersion and tail pinch tests. Intrathecal injections were performed with a total of 5  $\mu$ l of solution injected over 30 s. Following injections, subjects were tested on the tail immersion and tail pinch test. The intrathecal method used presently was independently validated by demonstrating maximal nociceptive activity of intrathecal morphine in at least 95% of injected subjects.

## 2.7. Statistics

Results are expressed in latencies, mean  $\pm$  S.E.M. Repeated measures analysis of variance (ANOVA) and planned comparisons were used to analyze the data (Statistica, CSS, Tulsa, OK).

## 3. Results

### 3.1. Systemic studies

Systemically administered immepip (50  $\mu$ g or 5 mg/kg, s.c.) had no effect on tail flick latencies in rats (Fig. 1A). However, the larger dose (5 mg/kg) produced significant antinociception on the tail pinch test 30 and 60 min post-injection (Fig. 1B). The smaller dose (50  $\mu$ g), shown below to be active intrathecally, was inactive after subcutaneous administration. In mice, large systemic doses of immepip (5 and 30 mg/kg, s.c.) failed to alter nociceptive responses on




Fig. 1. Effect of systemically administered immepip on nociceptive responses. Rats were tested for baseline responses (BL), then received immepip (50 µg or 5 mg/kg, s.c.) or saline vehicle. Tail flick (A) and tail pinch (B) latencies (ordinate, s, mean  $\pm$  S.E.M., number of subjects in parentheses) were recorded at the times shown after immepip injection (abscissa, min). \*\*\* $P < 0.01$ ,  $P < 0.001$  vs. saline at same time interval, respectively.

either the tail immersion or the tail pinch test (data not shown).

### 3.2. Rat intrathecal studies

When injected intrathecally, histamine  $H_3$  receptor agonists did not change nociceptive responses to the tail flick

test (data not shown) or the hot plate test (data not shown). In contrast, intrathecal administration of immepip (50 µg) produced nearly maximal antinociception on the tail pinch test (Fig. 2). Significant effects, seen as early as 5 min post-injection, remained significant over the course of 60 min, and declined thereafter. A lower dose of immepip (15 µg) produced mean nociceptive responses greater than those produced by saline; however, this effect was not statistically significant. Similar to the effect of immepip (50 µg), R- $\alpha$ -methylhistamine (50 µg), produced significant antinociception on the tail pinch test from 10 to 120 min post-injection.

In order to determine if the antinociceptive action of immepip is mediated by the histamine  $H_3$  receptor, the effect of the selective histamine  $H_3$  receptor antagonist thioperamide was determined on immepip antinociception (Fig. 3). Similar to what was seen in the previous experiment, nociceptive responses on the tail flick test were not altered by combinations of intrathecal immepip and subcutaneous thioperamide (data not shown). However, intrathecal immepip antinociception on the tail pinch test was abolished by subcutaneous pretreatment with thioperamide (Fig. 3A). In order to test the hypothesis that systemically administered immepip induces mechanical antinociception




Fig. 2. Effect of intrathecal histamine  $H_3$  receptor agonists on nociceptive responses. Rats were tested for baseline responses (BL) then received immepip (15 µg or 50 µg, i.t.), R- $\alpha$ -methylhistamine (RAMH, 50 µg), or saline vehicle. Tail pinch latencies (ordinate, s, mean  $\pm$  S.E.M., number of subjects in parentheses) were recorded at the times shown after histamine  $H_3$  receptor agonist injection (abscissa, min). \*\*\* $P < 0.05$ ,  $P < 0.01$  vs. saline at same time interval, respectively.

by action on spinal histamine  $H_3$  receptors, the effects of intrathecal thioperamide were studied after subcutaneous administration of immepip. In these experiments, mechanical antinociception produced by systemically administered immepip was completely reversed by intrathecal thioperamide treatment (Fig. 3B). Thioperamide alone did not alter nociceptive responses on any test.





Fig. 4. Effect of intrathecal immepip on nociceptive responses in wild type (wt) and  $H_3$  receptor knockout (ko) mice. Mice were tested for baseline responses (BL), then received immepip (imm, 10 or 25  $\mu$ g) or saline vehicle. Tail pinch latencies (ordinate, s, mean  $\pm$  S.E.M., number of subjects in parentheses) were recorded at the times shown after immepip injection (abscissa, min). \*\* $P < 0.001$  vs. saline of same genotype.

### 3.3. Mouse intrathecal studies

Intrathecal administration of immepip (25  $\mu$ g) in wild type and histamine  $H_3$  receptor knockout ( $H_3$ KO) mice produced no changes in nociceptive responses on the tail immersion test (data not shown). On the tail pinch test, however, this treatment produced maximal, reversible antinociception in wild type mice 5 and 10 min after administration (Fig. 4). On the same test, this treatment was completely without effect in  $H_3$ KO mice. A lower dose of immepip (10  $\mu$ g) produced mean nociceptive latencies at 5 min post-injection in wild type mice that were greater than those produced by saline; however, this effect was not statistically significant.

Fig. 3. Effect of thioperamide, a histamine  $H_3$  receptor antagonist, on immepip antinociception. Rats were tested for baseline responses (BL), then immediately received a subcutaneous injection of either thioperamide (A: thio, 10 mg/kg), immepip (B: imm, 5 mg/kg), or saline (A and B: sal). Thirty minutes later, baseline testing was repeated (A: 0; B: 30), followed by intrathecal injection of immepip (A: imm, 50  $\mu$ g.), thioperamide (B: thio, 20  $\mu$ g), or saline (A and B: sal). Tail pinch latencies (ordinate, s, mean  $\pm$  S.E.M., number of subjects in parentheses) were recorded at the times shown after immepip injection (abscissa, min). Data from A and B were from different subjects. \*\*\* $P < 0.05$ ,  $P < 0.005$  vs. sal/sal at the same time interval, respectively. +, ++ $P < 0.05$ ,  $P < 0.005$  vs. imm + sal at same time interval, respectively.

#### 4. Discussion

Several lines of evidence support the hypothesis that the activation of histamine  $H_3$  receptors attenuates mechanical nociception. First, the antinociception was dose-dependent (Fig. 2). Second, the antinociception was reversible (Figs. 1B–4). Third, two structurally different histamine  $H_3$  receptor agonists produced the effect (Fig. 2). Fourth, the antinociceptive effect of immapip was blocked by the selective histamine  $H_3$  receptor antagonist thioperamide in rats (Fig. 3). Finally, wild type, but not  $H_3$ KO mice, demonstrated mechanical antinociception after intrathecal administration of immapip (Fig. 4).

Present results offer considerable proof for a spinal site of action for the pain-modulatory effects of histamine  $H_3$  receptor agonists. Low doses of intrathecal immapip produced maximal mechanical antinociception in both rats (Figs. 2 and 3) and mice (Fig. 4). In rats, the intrathecal dose of immapip was not effective when administered systemically, suggesting that the effects of intrathecal immapip are localized to the spinal cord. In agreement with the idea of spinally located histamine  $H_3$  receptors, autoradiography studies performed with [ $^3H$ ]R- $\alpha$ -methylhistamine showed low-density, specific labeling of histamine  $H_3$  receptors in the superficial layers of the rat dorsal horn (Pollard et al., 1993). Also, *in situ* hybridization studies in rats revealed histamine  $H_3$  receptor mRNA in the sensory neurons of the dorsal horn and dorsal root ganglia (Heron et al., 2001). In rat spinal cord slices pre-labeled with [ $^3H$ ]noradrenaline, R- $\alpha$ -methylhistamine caused a decrease in electrically evoked [ $^3H$ ]noradrenaline release (Celuch, 1995), also suggesting localization of functional histamine  $H_3$  receptors in the spinal cord. Finally, unpublished immunohistochemical studies in our laboratory revealed intense histamine  $H_3$  receptor-like immunofluorescence in both the spinal cord and the dorsal root ganglia of mice (Cannon et al., unpublished).

Based on the findings of Figs. 1 and 2, systemically administered immapip could have been exerting its antinociceptive effects in rats peripherally, spinally, or supraspinally. R- $\alpha$ -methylhistamine does not reach the brain in measurable concentrations after systemic administration in rats and mice (Rouleau et al., 1997, 2000; Yamasaki et al., 1994), but comparable studies have not been performed with immapip. Thus, the degree of brain and spinal penetration in our experiments is unknown. However, immapip (5 mg/kg, s.c.) was shown to reduce histamine release in the anterior hypothalamus after systemic administration in rats (Jansen et al., 1998). Therefore, additional experiments were performed to directly evaluate the role of spinal histamine  $H_3$  receptors as a target for systemically administered immapip. When administered intrathecally, thioperamide completely reversed mechanical antinociception induced by systemically administered immapip (Fig. 3B). This experiment completely rules out peripheral and supraspinal sites of action since histamine  $H_3$  receptors at these sites

could not to have been blocked by such a low intrathecal dose of thioperamide (20  $\mu$ g). In addition, because subcutaneous administration of immapip induces antinociception in rats but not mice (Fig. 1), yet the same compound is effective after intrathecal treatment in both species, it is likely that systemic treatment in mice does not result in appreciable drug levels in the spinal cord. Thus, systemic administration of immapip in rats appears to induce mechanical antinociception via activation of spinal histamine  $H_3$  receptors.

Among many possible spinal sites of action, two targets for the inhibition of mechanical nociception by histamine  $H_3$  receptor agonists can be considered. First, histamine  $H_3$  receptors could be located on primary afferent fiber terminals, where they could inhibit the synthesis and/or release of neurotransmitters. Based upon the present results, histamine  $H_3$  receptors may not be located on fibers mediating thermal nociceptive transmission [i.e. polymodal C, C heat, and A $\delta$  Type II mechanoheat fibers (Beck et al., 1974; Yeomans and Proudfoot, 1996; Ringkamp et al., 2001)]. Because recent studies suggest that mechanical nociception is mediated primarily by capsaicin-insensitive A $\delta$  high threshold mechanoreceptors and A $\delta$  Type I mechanoheat nociceptors (Magerl et al., 2001; Ringkamp et al., 2001; Szolcsanyi et al., 1988), histamine  $H_3$  receptors might be localized on the central terminals of these types of nociceptive fibers.

The second possible spinal target for histamine  $H_3$  receptor agonists may be histamine  $H_3$  receptors on dendrites or soma of second order neurons. Current studies have revealed different types of modality-specific spinothalamic tract neurons originating from lamina I of the dorsal horn (Craig and Andrew, 2002). Lamina I is the region of the dorsal horn where A $\delta$  fibers primarily terminate. Histamine  $H_3$  receptors may be located on mechano-specific lamina I spinothalamic neurons, but this localization has not yet been established.

The present results confirm and extend findings by Rouleau et al. (1997) showing that activation of histamine  $H_3$  receptors does not attenuate thermal nociceptive responses. Based on the earlier findings, it seemed possible that poor penetration of the brain or spinal cord by orally administered histamine  $H_3$  receptor agonists might account for the absence of activity on thermal nociceptive (i.e. hot plate) responses. However, the present results, showing the same absence of activity on thermal nociceptive responses after systemically and intrathecally administered histamine  $H_3$  receptor agonists, indicate that the degree of penetration by these drugs into the spinal cord does not account for these findings.

The absence of histamine  $H_3$  receptor agonist and antagonist actions on thermal nociception found presently and by Rouleau et al. (1997) is in apparent contradiction with other findings. Two studies reported hyperalgesia on the mouse hot plate test after administration of very high doses of R- $\alpha$ -methylhistamine (100 mg/kg, i.p.; Malmberg-Aiello et al., 1994) and imetit (50 mg/kg, i.p.; Farzin et al., 2002).

Table 1

Intrathecal administered drugs that inhibit acute mechanical and thermal nociceptive transmission in animals and humans

Class	Examples of drugs	References
$\mu$ -Opioid agonist	Morphine, Endomorphin-1 and 2	(Abram, 1999) <sup>a,b</sup> (Przewlocki et al., 1999) <sup>a</sup>
$\alpha_2$ -Adrenergic agonist	Clonidine, Oxymetazoline	(Abram, 1999) <sup>a,b</sup> ; (Sherman et al., 1987) <sup>a</sup>
Muscarinic agonist	Oxotremorine	(Machelska et al., 1999) <sup>a</sup>
Adenosine receptor agonist	N6-cyclohexyladenosine, N-ethylcarboxiamidoadenosine	(Gouarderes et al., 2000) <sup>a</sup>
Neuropeptide FF analog	F8Famide, FMRFamide	(Gouarderes et al., 1993) <sup>a</sup>
COX inhibitor	Ketorolac	(Abram, 1999) <sup>a,b</sup>
P2Y agonist	UTP, UDP	(Okada et al., 2002) <sup>a</sup>
AMPA/KA receptor antagonist	LY293558	(Von Bergen et al., 2002) <sup>a</sup>
Acetylcholinesterase inhibitor	Neostigmine	(Abram, 1999) <sup>a,b</sup>

<sup>a</sup> Animals.

<sup>b</sup> Humans.

However, several studies have shown that much lower doses (e.g. 5 mg/kg, i.p.) of these histamine H<sub>3</sub> receptor agonists are sufficient to activate brain histamine H<sub>3</sub> receptors after systemic administration (Blandina et al., 1996; Farzin and Attarzadeh, 2000; Giovannini et al., 1999). Although the present studies did not measure hot plate latencies in mice after systemic administration of immepip, no effect of immepip was seen on another thermal assay (i.e. the mouse tail immersion test) after administration of histamine H<sub>3</sub> receptor-activating doses (5 and 30 mg/kg, s.c.). It is also noteworthy that the same studies (Malmberg-Aiello et al., 1994; Farzin et al., 2002) found slight antinociceptive activity on the mouse hot plate test after thioperamide treatment. We did not observe such effects with thioperamide in rats after systemic administration of a histamine H<sub>3</sub> receptor-blocking dose.

Many analgesics are effective after intrathecal administration in animals and man. A literature review of intrathecal drugs tested on both mechanical and thermal nociception has revealed that all are effective on both kinds of nociceptive stimuli in normal animals (Table 1). The present results suggest that histamine H<sub>3</sub> receptor agonists may differ from these other analgesics because they may attenuate mechanical but not thermal nociception. In fact, previous experiments indicate that separation of these modalities is possible (Kuraishi et al., 1985, 1991). However, results from studies with  $\mu$ - and  $\kappa$ -opioid agonists suggest that alleged modality-specific inhibition may instead result from a difference in stimulus intensities used in the tests (Parsons and Headley, 1989). Therefore, further

studies involving varying mechanical and thermal stimulus intensities are needed to confirm or refute the possibility of modality-specific inhibition of nociceptive transmission by histamine H<sub>3</sub> receptor agonists. The effects of histamine H<sub>3</sub> receptor agonists on mechanical nociceptive responses produced in tissues other than the tail also require further study. A previous study reported that systemic administration of R- $\alpha$ -methylhistamine (20 mg/kg, i.p.) had no effect on the rat paw pressure test up to 3 h post-injection, but produced slight hyperalgesia 4 to 7 h later (Malmberg-Aiello et al., 1994). It is unclear if using a different histamine H<sub>3</sub> agonist (i.e. immepip) and/or a different route of administration (i.e. intrathecal) would produce different outcomes on the rat paw pressure test. Although histamine H<sub>3</sub> receptor agonists seem to show antinociceptive activity on some forms of mechanical nociception, further studies are needed to evaluate the pain-relieving potential of these drugs.

### Acknowledgements

This work was supported by grants from the National Institute on Drug Abuse (DA-03816 and DA-07307). We thank Prof. Rob Leurs (Vrije University, Amsterdam, Netherlands) for the sample of immepip and Dr. Frank Rice (Albany Medical College, Albany, NY) for valuable discussions.

### References

- Abram, S.E., 1999. Spinally delivered analgesic drugs. In: Yaksh, T. (Ed.), *Spinal Drug Delivery*. Elsevier, Amsterdam, pp. 457–476.
- Arrang, J.M., Garbarg, M., Schwartz, J.C., 1983. Auto-inhibition of brain histamine release mediated by a novel class (H<sub>3</sub>) of histamine receptors. *Nature* 302, 832–837.
- Arrang, J.M., Garbarg, M., Lancelot, J., Lecomte, J.M., Pollard, H., Robba, M., Schunack, W., Schwartz, J.C., 1987. Highly potent and selective ligands for histamine H<sub>3</sub>-receptors. *Nature* 327, 117–123.
- Beck, P.W., Handwerker, H.O., Zimmermann, M., 1974. Nervous outflow from the cat's foot during noxious radiant heat stimulation. *Brain Res.* 67, 373–386.
- Bianchi, C., Franceschini, J., 1954. Experimental observations on Haffner's method for testing analgesic drugs. *Br. J. Pharmacol.* 9, 280–284.
- Blandina, P., Giorgetti, M., Bartolini, L., Cecchi, M., Timmerman, H., Leurs, R., Pepeu, G., Giovannini, M.G., 1996. Inhibition of cortical acetylcholine release and cognitive performance by histamine H<sub>3</sub> receptor activation in rats. *Br. J. Pharmacol.* 119, 1656–1664.
- Celuch, S.M., 1995. Possible participation of histamine H<sub>3</sub> receptors in the modulation of noradrenaline release from rat spinal cord slices. *Eur. J. Pharmacol.* 287, 127–133.
- Clark, E.A., Hill, S.J., 1996. Sensitivity of histamine H<sub>3</sub> receptor agonist-stimulated [<sup>35</sup>S]GTP gamma[S] binding to pertussis toxin. *Eur. J. Pharmacol.* 296, 223–225.
- Coge, F., Guenin, S.P., Audinot, V., Renouard-Try, A., Beauverger, P., Macia, C., Ouvre, C., Nagel, N., Rique, H., Boutin, J.A., Galizzi, J.P., 2001. Genomic organization and characterization of splice variants of the human histamine H<sub>3</sub> receptor. *Biochem. J.* 355, 279–288.
- Craig, A.D., Andrew, D., 2002. Responses of spinothalamic lamina I neu-



- rons to repeated brief contact heat stimulation in the cat. *J. Neurophysiol.* 87, 1902–1914.
- D'Amour, F.E., Smith, D.L., 1941. A method for determining loss of pain sensation. *J. Pharmacol. Exp. Ther.* 72, 74–79.
- Delaunois, A., Gustin, P., Garbarg, M., Ansary, M., 1995. Modulation of acetylcholine, capsaicin and substance P effects by histamine H<sub>3</sub> receptors in isolated perfused rabbit lungs. *Eur. J. Pharmacol.* 277, 243–250.
- Drutel, G., Peitsaro, N., Karlstedt, K., Wieland, K., Smit, M.J., Timmerman, H., Panula, P., Leurs, R., 2001. Identification of rat H<sub>3</sub> receptor isoforms with different brain expression and signaling properties. *Mol. Pharmacol.* 59, 1–8.
- Eddy, N.B., Leimbach, D., 1953. Synthetic analgesics: II. Dithienylbutenyl and dithienylbutylamines. *J. Pharmacol. Exp. Ther.* 107, 385–393.
- Farzin, D., Attarzadeh, M., 2000. Influence of different histamine receptor agonists and antagonists on apomorphine-induced licking behavior in rat. *Eur. J. Pharmacol.* 404, 169–174.
- Farzin, D., Asghari, L., Nowrouzi, M., 2002. Rodent antinociception following acute treatment with different histamine receptor agonists and antagonists. *Pharmacol. Biochem. Behav.* 72, 751–760.
- Giovannini, M.G., Bartolini, L., Bacciottini, L., Greco, L., Blandina, P., 1999. Effects of histamine H<sub>3</sub> receptor agonists and antagonists on cognitive performance and scopolamine-induced amnesia. *Behav. Brain Res.* 104, 147–155.
- Gouarderes, C., Sutak, M., Zajac, J.M., Jhamandas, K., 1993. Antinociceptive effects of intrathecally administered F8Famide and FMRFamide in the rat. *Eur. J. Pharmacol.* 237, 73–81.
- Gouarderes, C., Sutak, M., Zajac, J.M., Jhamandas, K., 2000. Role of adenosine in the spinal antinociceptive and morphine modulatory actions of neuropeptide FF analogs. *Eur. J. Pharmacol.* 406, 391–401.
- Hammond, D.L., 1988. Intrathecal administration: methodological considerations. In: Besson, J.M. (Ed.), *Progress in Brain Research*. Elsevier, New York, pp. 313–320.
- Harper, E.A., Shankley, N.P., Black, J.W., 1999. Evidence that histamine homologues discriminate between H<sub>3</sub>-receptors in guinea-pig cerebral cortex and ileum longitudinal muscle myenteric plexus. *Br. J. Pharmacol.* 128, 751–759.
- Heron, A., Rouleau, A., Cochois, V., Pillot, C., Schwartz, J.C., Arrang, J.M., 2001. Expression analysis of the histamine H(3) receptor in developing rat tissues. *Mech. Dev.* 105, 167–173.
- Hey, J.A., Del Prado, M., Egan, R.W., Kreutner, W., Chapman, R.W., 1992. (R)-alpha-methylhistamine augments neural, cholinergic bronchospasm in guinea pigs by histamine H<sub>1</sub> receptor activation. *Eur. J. Pharmacol.* 211, 421–426.
- Hill, S.J., Ganellin, C.R., Timmerman, H., Schwartz, J.C., Shankley, N.P., Young, J.M., Schunack, W., Levi, R., Haas, H.L., 1997. International Union of Pharmacology: XIII. Classification of histamine receptors. *Pharmacol. Rev.* 49, 253–278.
- Hough, L., 2001. Genomics meets histamine receptors: new subtypes, new receptors. *Mol. Pharmacol.* 59, 415–419.
- Hough, L., Leurs, R., 2002. Physiology and pharmacology of histamine receptors. In: Davis, C.H., Pangalos, M.N. (Eds.), *Structure and Function of GPCRs in the Nervous System*. Oxford Univ. Press, Oxford, pp. 307–348.
- Hylden, J.L., Wilcox, G.L., 1980. Intrathecal morphine in mice: a new technique. *Eur. J. Pharmacol.* 67, 313–316.
- Imamura, M., Smith, N.C., Garbarg, M., Levi, R., 1996. Histamine H<sub>3</sub>-receptor-mediated inhibition of calcitonin gene-related peptide release from cardiac C fibers. A regulatory negative-feedback loop. *Circ. Res.* 78, 863–869.
- Jansen, F.P., Mochizuki, T., Yamamoto, Y., Timmerman, H., Yamatodani, A., 1998. In vivo modulation of rat hypothalamic histamine release by the histamine H<sub>3</sub> receptor ligands, imbecip and clobenpropit. Effects of intrahypothalamic and peripheral application. *Eur. J. Pharmacol.* 362, 149–155.
- Krause, M., Rouleau, A., Stark, H., Luger, P., Lipp, R., Garbarg, M., Schwartz, J.C., Schunack, W., 1995. Synthesis, X-ray crystallography, and pharmacokinetics of novel azomethine prodrugs of (R)-alpha-methylhistamine: highly potent and selective histamine H<sub>3</sub> receptor agonists. *J. Med. Chem.* 38, 4070–4079.
- Kuraishi, Y., Hirota, N., Sato, Y., Hino, Y., Satoh, M., Takagi, H., 1985. Evidence that substance P and somatostatin transmit separate information related to pain in the spinal dorsal horn. *Brain Res.* 325, 294–298.
- Kuraishi, Y., Kawamura, M., Yamaguchi, T., Houtani, T., Kawabata, S., Futaki, S., Fujii, N., Satoh, M., 1991. Intrathecal injections of galanin and its antiserum affect nociceptive response of rat to mechanical, but not thermal, stimuli. *Pain* 44, 321–324.
- Lovenberg, T.W., Roland, B.L., Wilson, S.J., Jiang, X., Pyati, J., Huvar, A., Jackson, M.R., Erlander, M.G., 1999. Cloning and functional expression of the human histamine H<sub>3</sub> receptor. *Mol. Pharmacol.* 55, 1101–1107.
- Lovenberg, T.W., Pyati, J., Chang, H., Wilson, S.J., Erlander, M.G., 2000. Cloning of rat histamine H(3) receptor reveals distinct species pharmacological profiles. *J. Pharmacol. Exp. Ther.* 293, 771–778.
- Machelska, H., Pavone, F., Capone, F., Przewlocka, B., 1999. Antinociception after both peripheral and intrathecal injection of oxotremorine is modulated by spinal nitric oxide. *Eur. Neuropsychopharmacol.* 9, 213–217.
- Magerl, W., Fuchs, P.N., Meyer, R.A., Treede, R.D., 2001. Roles of capsaicin-insensitive nociceptors in cutaneous pain and secondary hyperalgesia. *Brain* 124, 1754–1764.
- Malmberg-Aiello, P., Lamberti, C., Ghelardini, C., Giotti, A., Bartolini, A., 1994. Role of histamine in rodent antinociception. *Br. J. Pharmacol.* 111, 1269–1279.
- Morisset, S., Rouleau, A., Ligneau, X., Ghahou, F., Tardivel-Lacombe, J., Stark, H., Schunack, W., Ganellin, C.R., Schwartz, J.C., Arrang, J.M., 2000. High constitutive activity of native H<sub>3</sub> receptors regulates histamine neurons in brain. *Nature* 408, 860–864.
- Nemmar, A., Delaunois, A., Beckers, J.F., Sulon, J., Bloden, S., Gustin, P., 1999. Modulatory effect of imetit, a histamine H<sub>3</sub> receptor agonist, on C-fibers, cholinergic fibers and mast cells in rabbit lungs in vitro. *Eur. J. Pharmacol.* 371, 23–30.
- Ohkubo, T., Shibata, M., Inoue, M., Kaya, H., Takahashi, H., 1995. Regulation of substance P release mediated via prejunctional histamine H<sub>3</sub> receptors. *Eur. J. Pharmacol.* 273, 83–88.
- Okada, M., Nakagawa, T., Minami, M., Satoh, M., 2002. Analgesic effects of intrathecal administration of P2Y nucleotide receptor agonists UTP and UDP in normal and neuropathic pain model rats. *J. Pharmacol. Exp. Ther.* 303, 66–73.
- Parsons, C.G., Headley, P.M., 1989. Spinal antinociceptive actions of mu- and kappa-opioids: the importance of stimulus intensity in determining 'selectivity' between reflexes to different modalities of noxious stimulus. *Br. J. Pharmacol.* 98, 523–532.
- Pollard, H., Moreau, J., Arrang, J.M., Schwartz, J.C., 1993. A detailed autoradiographic mapping of histamine H<sub>3</sub> receptors in rat brain areas. *Neuroscience* 52, 169–189.
- Przewlocki, R., Labuz, D., Mika, J., Przewlocka, B., Tomboly, C., Toth, G., 1999. Pain inhibition by endomorphins. *Ann. N.Y. Acad. Sci.* 897, 154–164.
- Ringkamp, M., Peng, Y.B., Wu, G., Hartke, T.V., Campbell, J.N., Meyer, R.A., 2001. Capsaicin responses in heat-sensitive and heat-insensitive A-fiber nociceptors. *J. Neurosci.* 21, 4460–4468.
- Rouleau, A., Garbarg, M., Ligneau, X., Manton, C., Lavie, P., Advenier, C., Lecomte, J.M., Krause, M., Stark, H., Schunack, W., Schwartz, J.C., 1997. Bioavailability, antinociceptive and antiinflammatory properties of BP 2-94, a histamine H<sub>3</sub> receptor agonist prodrug. *J. Pharmacol. Exp. Ther.* 281, 1085–1094.
- Rouleau, A., Stark, H., Schunack, W., Schwartz, J.C., 2000. Anti-inflammatory and antinociceptive properties of BP 2-94, a histamine H(3)-receptor agonist prodrug. *J. Pharmacol. Exp. Ther.* 295, 219–225.
- Sewell, R.D., Spencer, P.S., 1976. Antinociceptive activity of narcotic agonist and partial agonist analgesics and other agents in the tail-immersion test in mice and rats. *Neuropharmacology* 15, 683–688.
- Sherman, S., Loomis, C., Milne, B., Cervencko, F., 1987. Prolonged spinal

- analgesia in the rat with the alpha-adrenoceptor agonist oxymetazoline. *Eur. J. Pharmacol.* 140, 25–32.
- Storck, T., Kruth, U., Kolhekar, R., Sprengel, R., Seeburg, P.H., 1996. Rapid construction in yeast of complex targeting vectors for gene manipulation in the mouse. *Nucleic Acids Res.* 24, 4594–4596.
- Szolcsanyi, J., Anton, F., Reeh, P.W., Handwerker, H.O., 1988. Selective excitation by capsaicin of mechano-heat sensitive nociceptors in rat skin. *Brain Res.* 446, 262–268.
- Takahashi, K., Suwa, H., Ishikawa, T., Kotani, H., 2002. Targeted disruption of  $H_3$  receptors results in changes in brain histamine tone leading to an obese phenotype. *J. Clin. Invest.* 110, 1791–1799.
- Tardivel-Lacombe, J., Rouleau, A., Heron, A., Morisset, S., Pillot, C., Cochois, V., Schwartz, J.C., Arrang, J.M., 2000. Cloning and cerebral expression of the guinea pig histamine  $H_3$  receptor: evidence for two isoforms. *Neuroreport* 11, 755–759.
- Taylor, S.J., Michel, A.D., Kilpatrick, G.J., 1992. In vivo occupancy of histamine  $H_3$  receptors by thioperamide and (*R*)-alpha-methylhistamine measured using histamine turnover and an ex vivo labeling technique. *Biochem. Pharmacol.* 44, 1261–1267.
- Toyota, H., Dugovic, C., Koehl, M., Laposky, A.D., Weber, C., Ngo, K., Wu, Y., Lee, D.H., Yanai, K., Sakurai, E., Watanabe, T., Liu, C., Chen, J., Barbier, A.J., Turek, F.W., Fung-Leung, W.P., Lovenberg, T.W., 2002. Behavioral characterization of mice lacking histamine  $H(3)$  receptors. *Mol. Pharmacol.* 62, 389–397.
- Vollinga, R.C., de Koning, J.P., Jansen, F.P., Leurs, R., Menge, W.M., Timmerman, H., 1994. A new potent and selective histamine  $H_3$  receptor agonist, 4-(1 *H*-imidazol-4-ylmethyl)piperidine. *J. Med. Chem.* 37, 332–333.
- Von Bergen, N.H., Subieta, A., Brennan, T.J., 2002. Effect of intrathecal non-NMDA EAA receptor antagonist LY293558 in rats: a new class of drugs for spinal anesthesia. *Anesthesiology* 97, 177–182.
- Wellendorph, P., Goodman, M.W., Burstein, E.S., Nash, N.R., Brann, M.R., Weiner, D.M., 2002. Molecular cloning and pharmacology of functionally distinct isoforms of the human histamine  $H(3)$  receptor. *Neuropharmacology* 42, 929–940.
- Yaksh, T., Rudy, T.A., 1976. Chronic catheterization of the spinal subarachnoid space. *Physiol. Behav.* 17, 1031–1036.
- Yamasaki, S., Sakurai, E., Hikichi, N., Sakai, N., Maeyama, K., Watanabe, T., 1994. The disposition of (*R*)-alpha-methylhistamine, a histamine  $H_3$ -receptor agonist, in rats. *J. Pharm. Pharmacol.* 46, 371–374.
- Yeomans, D.C., Proudfit, H.K., 1996. Nociceptive responses to high and low rates of noxious cutaneous heating are mediated by different nociceptors in the rat: electrophysiological evidence. *Pain* 68, 141–150.